AR039409A1 - Composicion farmaceutica en polvo seco para inhalacion, fabricacion y uso. - Google Patents

Composicion farmaceutica en polvo seco para inhalacion, fabricacion y uso.

Info

Publication number
AR039409A1
AR039409A1 ARP030101280A ARP030101280A AR039409A1 AR 039409 A1 AR039409 A1 AR 039409A1 AR P030101280 A ARP030101280 A AR P030101280A AR P030101280 A ARP030101280 A AR P030101280A AR 039409 A1 AR039409 A1 AR 039409A1
Authority
AR
Argentina
Prior art keywords
dry powder
inhalation
pharmaceutical composition
derivatized
treatment
Prior art date
Application number
ARP030101280A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR039409A1 publication Critical patent/AR039409A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composiciones farmacéuticas en polvo y a su uso en el tratamiento de trastornos respiratorios por inhalación. También inhaladores de polvo seco que comprenden las mismas. Más particularmente, se describen composiciones farmacéuticas de polvo seco de estabilidad mejorada. Los inhaladores de polvo seco (IPS) son dispositivos bien conocidos para administrar agentes farmacéuticamente activos al tracto respiratorio. En consecuencia, son particularmente adecuados cuando se utilizan para la administración de agentes activos en el tratamiento de enfermedades tales como asma, bronquitis, enfermedad obstructiva crónica (EPOC), enfisema, rinitis, etc. Reivindicación 1: el uso de carbohidratos derivatizados particulados en composiciones farmacéuticas en polvo seco para terapia por inhalación para mejorar el comportamiento de estabilidad. Reivindicación 3: una composición farmacéutica en polvo seco para terapia por inhalación, que comprende un agente farmacéuticamente activo, un excipiente y un carbohidrato derivatizado en forma pariculada. Reivindicación 7: Una composición farmacéutica en polvo seco según la reivindicación 3, en la que el carbohidrato derivatizado es octaacetato de alfa-D-celobiosa.
ARP030101280A 2002-04-13 2003-04-11 Composicion farmaceutica en polvo seco para inhalacion, fabricacion y uso. AR039409A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0208608.0A GB0208608D0 (en) 2002-04-13 2002-04-13 Composition

Publications (1)

Publication Number Publication Date
AR039409A1 true AR039409A1 (es) 2005-02-16

Family

ID=9934855

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101280A AR039409A1 (es) 2002-04-13 2003-04-11 Composicion farmaceutica en polvo seco para inhalacion, fabricacion y uso.

Country Status (19)

Country Link
US (1) US20050244340A1 (es)
EP (1) EP1494644A1 (es)
JP (1) JP2005530733A (es)
KR (1) KR20040099436A (es)
CN (1) CN1658839A (es)
AR (1) AR039409A1 (es)
AU (1) AU2003217073A1 (es)
BR (1) BR0309114A (es)
CA (1) CA2481467A1 (es)
GB (1) GB0208608D0 (es)
IL (1) IL164420A0 (es)
IS (1) IS7500A (es)
MX (1) MXPA04010080A (es)
NO (1) NO20044497L (es)
PL (1) PL373294A1 (es)
RU (1) RU2004130439A (es)
TW (1) TW200404008A (es)
WO (1) WO2003088943A1 (es)
ZA (1) ZA200408245B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8337816B2 (en) 2001-09-17 2012-12-25 Glaxo Group Limited Dry powder medicament formulations
SE526509C2 (sv) * 2003-06-19 2005-09-27 Microdrug Ag Kombinerade doser av formoterol och budesonid separerade på en gemensam dosbädd
JP2009513529A (ja) * 2003-07-11 2009-04-02 グラクソ グループ リミテッド ステアリン酸マグネシウムを含む医薬製剤
WO2005004846A1 (en) * 2003-07-11 2005-01-20 Glaxo Group Limited Pharmaceutical formulations
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
WO2006066907A1 (en) * 2004-12-21 2006-06-29 Glaxo Group Limited Pharmaceutical formulations
CN104177448A (zh) 2005-02-10 2014-12-03 葛兰素集团有限公司 使用预分选技术制备乳糖的方法以及由此形成的药物制剂
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
US20090325952A1 (en) 2006-08-01 2009-12-31 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
GB0921075D0 (en) * 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
AU2014261538A1 (en) * 2013-04-29 2015-12-10 Sanofi Sa Inhalable pharmaceutical compositions and the inhaler devices containing them
WO2016019355A1 (en) * 2014-08-01 2016-02-04 Luxena Pharmaceuticals, Inc. Palonosetron formulations and uses thereof
PT109030B (pt) * 2015-12-15 2019-09-25 Hovione Farmaciência, S.A. Preparação de partículas inaláveis de zafirlucaste
CN110237373B (zh) * 2018-03-08 2023-06-02 润生药业有限公司 一种生产用于联合用药的药物载体的装置及方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR8007911A (pt) * 1979-12-06 1981-06-16 Glaxo Group Ltd Inalador aperfeicoado
SE448277B (sv) * 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
US4811731A (en) * 1985-07-30 1989-03-14 Glaxo Group Limited Devices for administering medicaments to patients
GB9004781D0 (en) * 1990-03-02 1990-04-25 Glaxo Group Ltd Device
JPH04220268A (ja) * 1990-12-19 1992-08-11 Olympus Optical Co Ltd バルーンカテーテル
ZA9711732B (en) * 1996-12-31 1998-12-28 Quadrant Holdings Cambridge Methods and compositions for improvement bioavailability of bioactive agents for mucosal delivery
DK0994887T3 (da) * 1997-07-03 2003-03-17 Elan Drug Delivery Ltd Modificerede glycosider, præparater omfattet deraf og fremgangsmåder til anvendelse deraf
US6352722B1 (en) * 1997-12-23 2002-03-05 Quadrant Holdings Cambridge Limited Derivatized carbohydrates, compositions comprised thereof and methods of use thereof
CA2347856C (en) * 1998-11-13 2009-02-17 Jago Research Ag Dry powder for inhalation
GB9916316D0 (en) * 1999-07-12 1999-09-15 Quadrant Holdings Cambridge Dry powder compositions
GB0015981D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
GB0020616D0 (en) * 2000-08-21 2000-10-11 Quadrant Holdings Cambridge Particulates
WO2002043750A2 (en) * 2000-12-01 2002-06-06 Battelle Memorial Institute Method for the stabilizing of biomolecules (e.g. insulin) in liquid formulations
GB0103630D0 (en) * 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
PL373294A1 (en) 2005-08-22
TW200404008A (en) 2004-03-16
ZA200408245B (en) 2007-03-28
IL164420A0 (en) 2005-12-18
JP2005530733A (ja) 2005-10-13
AU2003217073A1 (en) 2003-11-03
CN1658839A (zh) 2005-08-24
RU2004130439A (ru) 2005-06-10
US20050244340A1 (en) 2005-11-03
IS7500A (is) 2004-10-11
GB0208608D0 (en) 2002-05-22
CA2481467A1 (en) 2003-10-30
MXPA04010080A (es) 2004-12-13
BR0309114A (pt) 2005-02-01
NO20044497L (no) 2004-11-15
EP1494644A1 (en) 2005-01-12
WO2003088943A1 (en) 2003-10-30
KR20040099436A (ko) 2004-11-26

Similar Documents

Publication Publication Date Title
PT1326595E (pt) Composicao farmaceutica compreendendo resveratrol para o tratamento de disturbios respiratorios inflamatorios
AR039409A1 (es) Composicion farmaceutica en polvo seco para inhalacion, fabricacion y uso.
BR0308274A (pt) Formulação de formoterol superfino
NO20061254L (no) Farmasoytiske blandinger
RU2018138195A (ru) Соединения 3,5-диамино-6-хлор-n-(n-(4- фенилбутил)карбамимидоил)пиразин-2-карбоксамида
RS52940B (en) PHARMACEUTICAL FORMULATIONS OF SOLUTION FOR MEASURED DOSES OF PRESSURE INHALATORS
UY26959A1 (es) Nuevos polvos para inhalación que contienen tiotropio
US20110189106A1 (en) Intranasal compositions, dosage forms and methods of treatment
NO20024708L (no) Behandling av respiratoriske sykdommer
NO20075042L (no) Farmasoytisk sammensetning innbefattende en omega-karboksyarylsubstituert difenylurea for behandling av cancer
AR015820A1 (es) Particulas de budesonida, composicion farmaceutica, uso de dichas particulas para la fabricacion de medicamentos, metodo para el tratamiento de untrastorno respiratorio y proceso para la preparacion de las particulas
CA2474479A1 (en) Composition for inhalation
HRP20220929T3 (hr) Sastav za inhalaciju koji sadrži aklidinij za liječenje astme
NO20054767L (no) Sammensetninger omfattende apomorfin for inhalering i lunge
AR039408A1 (es) Composicion farmaceutica en polvo seco para terapia por inhalacion y uso para fabricacion de un medicamento
MXPA05009629A (es) Composiciones que contienen trospio.
BR0306663A (pt) Formulação de salmeterol superfino
PE20020793A1 (es) Agente preventivo y/o terapeutico de enfermedades inflamatorias del tracto respiratorio
RU2007138263A (ru) Противовоспалительные соединения
UY30935A1 (es) Combinacion:-antagonista del receptor de quimioquina 1 (ccr1) -agonista del receptor de glucocorticoides- opcionalmente agonista b(beta)2, -composicion farmacéutica conteniéndola -aplicaciones.
EA200600886A1 (ru) Способ получения солей тиотропия, соли тиотропия, а также содержащие их лекарственные композиции
WO2005011604A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
NZ597657A (en) Use sulphur particles less than 300 microns and sodium lignin sulfonate for treating diseases casused by microbial pathogenic infections
UY28096A1 (es) Nueva formulación pulveurlenta que contiene tiotropio destinada a la inhalación
WO2007046113A3 (en) Novel pharmaceutical composition comprising alkaloid and process thereof

Legal Events

Date Code Title Description
FA Abandonment or withdrawal